Transcenta and Agilent Technologies Join Forces for Developing Claudin18.2 Companion Diagnostic to Support the P-III Study of Osemitamab
Shots:
- Transcenta & Agilent have partnered for the development of CLDN18.2 companion diagnostic that will support P-III (TranStar301) study of osemitamab + nivolumab & CT as a 1L treatment of CLDN18.2 expressing locally advanced or metastatic G/GEJ adenocarcinoma
- Under the collaboration, Transcenta will develop clone 14G11, a mouse anti-CLDN18.2 mAb comprising of a binding site that overlaps with the binding site of osemitamab, for its utilization in companion diagnostic assay
- Additionally, Agilent is working on the CLDN18.2 IHC 14G11 pharmDx assay to detect CLDN18.2 protein in G/GEJ adenocarcinoma with its applications in other indications. It will be used for patient selection in the P-III trials of G/GEJ adenocarcinoma
Ref: Transcenta | Image: Transcenta
Related News:- Transcenta Reports First Patient Dosing in P-I Study of TST002 for the Treatment of Osteoporosis in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
